Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02406209 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
A Phase 2 study, sponsored by Aldeyra Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02406209 is a Phase 2 study that has completed, run by Aldeyra Therapeutics. The registered enrollment target is 45 participants.
The verdict
NCT02406209, a Phase 2 study, has completed, sponsored by Aldeyra Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and Pred Forte® 1%, or Pred Forte® 1%. Free aldehydes are thought to be related to inflammatory diseases such as uveitis. NS2, a small molecule aldehyde trap, may decrease inflammation by lowering aldehyde levels.
Interventions
- DRUG NS2
- DRUG Prednisolone acetate ophthalmic suspension (1%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02406209
The ClinicalTrials.gov registry entry for NCT02406209 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aldeyra Therapeutics, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NS2 is the first listed.
NCT02406209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02406209 about?
NCT02406209 is a clinical study titled "A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis". This is a randomized, multi-center, investigator masked, comparator controlled study. The purpose of this study is to determine the efficacy and safety of NS2 in patients with non-infectious acute anterior uveitis. Subjects will be randomized 1:1:1 to receive multiple doses of NS2 0.5%, NS2 0.5% and...
What is the current status of trial NCT02406209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-03. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02406209?
The interventions under investigation include: NS2 (DRUG), Prednisolone acetate ophthalmic suspension (1%) (DRUG).
Who is sponsoring clinical trial NCT02406209?
This trial is sponsored by Aldeyra Therapeutics, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.